Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s resubmission of its BLA for Awiqli, the FDA’s approval of Kedrion’s Qivigy for primary humoral immunodeficiency, and Eli Lilly’s decision to halt development of a muscle-preserving weight-loss therapy. Novo Nordisk has resubmitted its biologics license application to the FDA for Awiqli, its investigational weekly insulin. With the resubmission, Novo aims to move forward with its first weekly insulin, a therapy that could reduce the burden of daily injections for millions of people living with diabetes. Thanks for listening to Pharmaceutical Executive Daily.